Literature DB >> 9452008

Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex.

W J Lukiw1, N G Bazan.   

Abstract

Long-term treatment by nonsteroidal anti-inflammatory drugs has been shown to decrease the incidence of Alzheimer's disease (AD). Both platelet-activating factor and interleukin-1beta, potent mediators of the inflammatory and immune response, strongly induce transcription of the cyclooxygenase-2 (COX-2) gene in brain cells. Using Northern and RT-PCR analysis, we have determined in 15 control and 10 sporadic AD human neocortical samples (age range, 60-82 yr; postmortem interval [PMI] range, 0.7-16.0 hr) the levels of COX-2 RNA in relation to the constitutively expressed COX-1 and beta-actin RNA message levels. Our results indicate that in short PMI brain, COX-1 and COX-2 transcripts are relatively low abundance RNA messages, ranging from a mean of 6.8% of the beta-actin signal in controls to 8.5% of the beta-actin signal in AD-affected brain. A large variation in the signal intensity for COX-2 RNA was noted in both control and AD; although there was a trend for higher COX-2 RNA message abundance in AD neocortex to +11.5% of that of controls, it did not reach statistical significance (ANOVA = 0.45). Several human tissues, including heart, skeletal muscle, lung, kidney, and spinal cord, displayed 4.6- and 2.8-kb COX-2 RNA message isoforms; however, the 4.6-kb COX-2 RNA predominated in the hippocampus and association neocortex. COX-2 RNA message was found to be degraded at similar rates in both control and AD tissues, and a strong positive correlation between the PMI and the intensity of the COX-2 RNA signal was noted (ANOVA = 0.006). Linear regression analysis indicated that the 4.6-kb COX-2 RNA is an unstable short-lived RNA species with a half-life of not more than 3.5 hr, a feature characteristic of immediate early gene transcripts. Individual hypervariability in COX-2 RNA message abundance may reflect various degrees of expression of AD-related inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9452008     DOI: 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  40 in total

1.  Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome.

Authors:  W J Lukiw; P Dua; A I Pogue; C Eicken; J M Hill
Journal:  J Toxicol Environ Health A       Date:  2011

2.  Alternative polyadenylation produces two major transcripts of Alix.

Authors:  Zhehui Feng; Chuan Fen Wu; Xi Zhou; Jian Kuang
Journal:  Arch Biochem Biophys       Date:  2007-07-01       Impact factor: 4.013

Review 3.  Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease.

Authors:  Thomas J Montine; Randall L Woltjer; Catherine Pan; Kathleen S Montine; Jing Zhang
Journal:  NeuroRx       Date:  2006-07

4.  Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3'-UTR.

Authors:  Tyra Hall-Pogar; Songchun Liang; Lisa K Hague; Carol S Lutz
Journal:  RNA       Date:  2007-05-16       Impact factor: 4.942

Review 5.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

6.  Expression of COX-1 and COX-2 in a clinical model of acute inflammation.

Authors:  Asma A Khan; Michael Iadarola; Hsiu-Ying T Yang; Raymond A Dionne
Journal:  J Pain       Date:  2007-01-30       Impact factor: 5.820

Review 7.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

Review 8.  RNA expression analysis from formalin fixed paraffin embedded tissues.

Authors:  Susan M Farragher; Austin Tanney; Richard D Kennedy; D Paul Harkin
Journal:  Histochem Cell Biol       Date:  2008-08-05       Impact factor: 4.304

9.  Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

Authors:  Daniela L Krause; Norbert Müller
Journal:  Int J Alzheimers Dis       Date:  2010-06-14

10.  Comprehensive mRNA expression profiling distinguishes tauopathies and identifies shared molecular pathways.

Authors:  Iraad F Bronner; Zoltán Bochdanovits; Patrizia Rizzu; Wouter Kamphorst; Rivka Ravid; John C van Swieten; Peter Heutink
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.